Cancer Metabolomics 2018

The metabolomics approach, defined as the study of all endogenously-produced low-molecular-weight compounds, appeared as a promising strategy to define new cancer biomarkers. Information obtained from metabolomic data can help to highlight disrupted cellular pathways and, consequently, contribute to...

Full description

Saved in:
Bibliographic Details
:
Year of Publication:2019
Language:English
Physical Description:1 electronic resource (184 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03632nam-a2200925z--4500
001 993548226304498
005 20231214132858.0
006 m o d
007 cr|mn|---annan
008 202102s2019 xx |||||o ||| 0|eng d
020 |a 3-03921-346-6 
035 |a (CKB)4100000010106110 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/42643 
035 |a (EXLCZ)994100000010106110 
041 0 |a eng 
100 1 |a Pinto, Joana  |4 auth 
245 1 0 |a Cancer Metabolomics 2018 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2019 
300 |a 1 electronic resource (184 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a The metabolomics approach, defined as the study of all endogenously-produced low-molecular-weight compounds, appeared as a promising strategy to define new cancer biomarkers. Information obtained from metabolomic data can help to highlight disrupted cellular pathways and, consequently, contribute to the development of new-targeted therapies and the optimization of therapeutics. Therefore, metabolomic research may be more clinically translatable than other omics approaches, since metabolites are closely related to the phenotype and the metabolome is sensitive to many factors. Metabolomics seems promising to identify key metabolic pathways characterizing features of pathological and physiological states. Thus, knowing that tumor metabolism markedly differs from the metabolism of normal cells, the use of metabolomics is ideally suited for biomarker research. Some works have already focused on the application of metabolomic approaches to different cancers, namely lung, breast and liver, using urine, exhaled breath and blood. In this Special Issue we contribute to a more complete understanding of cancer disease using metabolomics approaches. 
546 |a English 
653 |a cell transporters 
653 |a pharmacodynamics 
653 |a cell growth 
653 |a in vitro study 
653 |a metabolomic signatures 
653 |a endometabolome 
653 |a lung cancer 
653 |a metabolomics 
653 |a chemometric methods 
653 |a bladder cancer 
653 |a mTOR 
653 |a metabolite profiling 
653 |a metabolic pathways 
653 |a hepatocellular carcinoma 
653 |a glutamate 
653 |a senescence MCF7 
653 |a breath analysis 
653 |a bio actives 
653 |a biomarker 
653 |a gas chromatography–mass spectrometry (GC–MS) 
653 |a GC-MS 
653 |a lung 
653 |a omics 
653 |a nutraceuticals 
653 |a glutaminase 
653 |a metabolism 
653 |a acylcarnitines 
653 |a Erwinaze 
653 |a Kidrolase 
653 |a glutathione 
653 |a targeted metabolomics 
653 |a apoptosis 
653 |a SLC1A5 
653 |a essential amino acids 
653 |a cancer progression 
653 |a ASCT2 
653 |a HR MAS 
653 |a alanine 
653 |a analytical platforms 
653 |a volatile organic compound 
653 |a glutaminolysis 
653 |a isotope tracing analysis 
653 |a asparaginase 
653 |a vitamin E 
653 |a breast cancer 
653 |a prognosis 
653 |a early diagnosis 
653 |a tocotrienols 
653 |a NMR 
653 |a prostate cancer 
653 |a in vitro 
653 |a cancer 
653 |a MDA-MB-231 
776 |z 3-03921-345-8 
700 1 |a Carvalho, Márcia  |4 auth 
700 1 |a De Pinho, Paula Guedes  |4 auth 
906 |a BOOK 
ADM |b 2024-02-27 23:13:14 Europe/Vienna  |f system  |c marc21  |a 2020-02-01 22:26:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338820410004498&Force_direct=true  |Z 5338820410004498  |b Available  |8 5338820410004498